Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	184 Pages	Coherent Market Insights	November, 2021	CMI16854976

Best Price Guarantee
Price	from $4,500
Length	184 Pages
Publisher	Coherent Market Insights
Published Date	November, 2021
SKU	CMI16854976

Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3) and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Bile duct cancer, also known as cholangiocarcinoma, is a type of cancer that forms in the bile ducts. The symptoms of bile duct cancer may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever.

Increasing prevalence of bile duct cancer has driven the market growth, For instance, according to American Cancer Society report 2018, each year around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.

Market Dynamics

Key players are focusing on product approvals to strengthen their position in the global bile duct cancer market. In February 2021, Eisai Co., Ltd., a pharmaceutical company, received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its Fibroblast Growth Factor (FGF) receptor selective tyrosine kinase inhibitor E7090.

Key features of the study:

This report provides an in-depth analysis of the global bile duct cancer market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bile duct cancer market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market

Detailed Segmentation:

Global Bile Duct Cancer market, By Treatment Type:
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
Global Bile Duct Cancer market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Bile Duct Cancer market, By Region:
North America
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Chemotherapy
Gemcitabine
Cisplatin
Oxaliplatin
Oxaliplatin
5 fluorouracil (5-FU)
Targeted Therapy
Pemigatinib
Infigratinib (Phase 3)
Ivosidenib (Phase 3)
Immunotherapy
Pembrolizumab (Phase 3)
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Incyte Corporation*
Company Overview
Product Portfolio
Financial Overview
Key Highlights
Market Strategies
Eisai Co., Ltd.
QED Therapeutics, Inc.
Agios Pharmaceuticals, Inc.
RenovoRx
Ability Pharmaceuticals
Imbrium Therapeutics L.P.
Delcath Systems, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Treatment Type; Market Snippet, By Distribution Channel; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Drivers; Restraints; Opportunity; Impact Analysis; Pipeline Analysis; Regulatory Scenario; Market Trends; Key Developments; Epidemiology; PEST Analysis; Brand Analysis
4. Global Bile Duct Cancer market – Impact of Coronavirus (Covid-19) Pandemic: Economic Impact; COVID-19 Epidemiology; Impact on Clinical Trials and Drug Development; Government Initiatives
5. Global Bile Duct Cancer market, By Treatment Type, 2021 – 2028, (US$ Mn): Introduction; Market Share Analysis, 2021 and 2028 (%); Y-o-Y Growth Analysis, 2018 – 2028; Segment Trends; Chemotherapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn); Gemcitabine; Cisplatin; Oxaliplatin; Oxaliplatin; 5 fluorouracil (5-FU); Targeted Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn); Pemigatinib; Infigratinib (Phase 3); Ivosidenib (Phase 3); Immunotherapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn); Pembrolizumab (Phase 3); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
6. Global Bile Duct Cancer market, By Distribution Channel, 2021 – 2028, (US$ Mn): Introduction; Market Share Analysis, 2021 and 2028 (%); Y-o-Y Growth Analysis, 2018 – 2028; Segment Trends; Hospital Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
7. Global Bile Duct Cancer market, By Region, 2021 – 2028, (US$ Mn): Introduction; Market Share Analysis, By Region, 2021 and 2028 (%); Y-o-Y Growth Analysis, For Regions, 2018–2028; North America; Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn); U.S.; Canada; Latin America; Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn); Germany; U.K.; France; Italy; Spain; Russia; Rest of Europe; Asia Pacific; Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn); China; India; Japan; Australia; South Korea; ASEAN; Rest of Asia Pacific; Middle East; Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn); GCC; Israel; Rest of Middle East; Africa; Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn); Market Size and Forecast, By Region/Country, 2021 – 2028, (US$ Mn); South Africa; Central Africa; North Africa
8. Competitive Landscape: Competitive Snapshot; Incyte Corporation*; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Eisai Co., Ltd.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; QED Therapeutics, Inc.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Agios Pharmaceuticals, Inc.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; RenovoRx; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Ability Pharmaceuticals; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Imbrium Therapeutics L.P.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies; Delcath Systems, Inc.; Company Overview; Product Portfolio; Financial Overview; Key Highlights; Market Strategies
9. Section: References; Research Methodology; About us and Sales Contact; *Browse 26 market data tables and 27 figures on "Bile Duct Cancer market” - Global forecast to 2028

Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3)

May, 2022 | Published by: Coherent Market Insights | USD $4,500
Cholangiocarcinoma Market, By Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy, and Others), By Distrib

May, 2022 | Published by: Coherent Market Insights | USD $4,500
Cholangiocarcinoma Market, By Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, and 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

May, 2021 | Published by: Coherent Market Insights | USD $4,500
Esophageal Cancer Drugs Market, By Therapy Type (Chemotherapy (Docetaxel, Irinotecan, Trifluridine and Tipiracil, Carboplatin and Paclitaxel, Cisplatin and 5-fluorouracil, and Cisplatin with Capecitabine), Targeted Drug Therapy (Trastuzumab and Ramuciruma

May, 2022 | Published by: Coherent Market Insights | USD $4,500
Anal Cancer Market, by Drug Type (Fluorouracil, Cisplatin, Carboplatin, and Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)), by Cancer Type (Carcinoma In-situ, Squamous Cell Carcinoma, Melanoma, Adenocarcinoma, and Basal Cell

May, 2022 | Published by: Coherent Market Insights | USD $4,500
Bile Duct Cancer - Market Insight, Epidemiology and Market Forecast -2032

January, 2022 | Published by: DelveInsight | USD $7,500

PDF E-mail From Publisher:	$4,500
Site License Fulfilled by Publisher:	$7,000
Global Site License Fulfilled by Publisher:	$10,000

Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3)

Research Assistance

Other tasks

Bile Duct Cancer Market, by Treatment Type (Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine and 5 fluorouracil (5-FU), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), and Ivosidenib (Phase 3), Immunotherapy (Pembrolizumab (Phase 3)